The U.S. National Institutes of Health said on Wednesday it had started a mid-term study to determine the risk of allergic reactions to COVID-19 vaccines made by Moderna Inc and Pfizer Inc.
Several incidents of allergic reaction, including severe episodes, known as anaphylaxis, have been reported in the United States after the Pfizer / BioNTech and Moderna vaccinations.
In January, the U.S. Centers for Disease Control and Prevention said allergic reactions were occurring at a rate of 11.1 per 1 million vaccinations.
The study, funded by the National Institute of Allergy and Infectious Diseases, will recruit 3,400 adults between the ages of 18 and 69, with about 60% of participants having a history of severe allergic reactions to food, insect bites or immunotherapy.
The aim of the trial is to access the proportion of participants who have a systemic allergic reaction within 90 minutes of the injection.
The agency plans to release data later this summer.
(This story was not edited by The Bharat Express News on Social Platforms.)